|
|
|
Solid Biosciences Inc (NASDAQ: SLDB) |
|
Solid Biosciences Inc
Officers & Directors
Rajeev Shah Director Georgia Keresty Director Adam Koppel Director Boston, Massachusetts Martin Freed Director Lynne Sullivan Director Ian F. Smith Chairman of the Board Adam Stone Director Clare Kahn Director Sukumar Nagendran Director Alexander Cumbo President, Chief Executive Officer and Director (Principal Executive Officer) Kevin Tan Chief Financial Officer (Principal Financial and Accounting Officer) Ilan Ganot Director ,
Solid Biosciences Inc currently has 121 employees.
News about Solid Biosciences Inc Key Personnel |
Outlining the Facts:1. Underwritten Offering: - Solid Biosciences Inc. priced an underwritten offering of 35,739,810 shares at $4.03 per share and pre-funded warrants for 13,888,340 shares at $4.029 each. - The total gross proceeds from this offering are expected to be approximately $200 million. - The financing round is intended to support ongoing development in precision genetic medicines for neuromuscular and cardiac diseases. - The offering is expected to close on February 19, 2025, pending standard closing conditions.2. Financial Challenges: - The company reported a cumulative net loss of $102 million for the twelve months ending in Q3 2024. - Solid Biosciences has a negative return on asset...
|
Solid Biosciences Inc. a trailblazer in the field of precision genetic therapies, has recently garnered attention with the FDA’s Fast Track designation for its dual-route gene therapy, SGT-212, aimed at treating Friedreich s ataxia (FA). This is a significant milestone as SGT-212 is the only dual-route gene transfer therapy under development that has received FDA Investigational New Drug (IND) clearance, positioning Solid as a unique player in this therapeutic landscape. However, the company is also grappling with significant financial challenges, as reflected in its latest financial disclosures. Financial PositionIn reporting a cumulative net loss of $102 million for the twelve months ending in the third ...
|
Solid Biosciences Grants Inducement Awards to Newly Hired Employees, Share Price Dips in Q2 2024
CHARLESTOWN, Mass., April 03, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a leading life sciences company focusing on precision genetic medicines for neuromuscular and cardiac diseases, has recently announced the granting of inducement awards to two individuals who have joined the organization. These grants were awarded as part of the company s 2024 Inducement Stock Incentive Plan and were intended to serve as motivation for the employees to accept their positions at Solid Biosciences, in compliance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences, recognized for its pioneering work and commitment...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
